Because TNF-α and IL-1 β production were substantially and long-term inhibited during IL-10 treatment, it was previously tested in the clinical treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (Wang et al., 2019). The gene discussed is IL10; the disease is rheumatoid arthritis.